Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients

• Published in: The Journal of infectious diseases Vol. 221; no. 7; pp. 1117 - 1126
• Main Authors: Douglas, Cameron M, Barnard, Richard, Holder, Daniel, Leavitt, Randi, Levitan, Diane, Maguire, Maureen, Nickle, David, Teal, Valerie, Wan, Hong, van Alewijk, Dirk C J G, van Doorn, Leen-Jan, Chou, Sunwen, Strizki, Julie
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 16.03.2020
• Subjects: Acetates - pharmacology; Acetates - therapeutic use; Antibiotic Prophylaxis; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Antiviral drugs; Cell culture; Clinical trials; Clinical Trials, Phase III as Topic; Cytomegalovirus; Cytomegalovirus - drug effects; Cytomegalovirus - genetics; Cytomegalovirus Infections - drug therapy; Cytomegalovirus Infections - prevention & control; Cytomegalovirus Infections - virology; Deoxyribonucleic acid; DNA; Drug Resistance, Viral - drug effects; Drug Resistance, Viral - genetics; Ganciclovir; Genotyping; Hematopoietic Stem Cell Transplantation; Hematopoietic stem cells; Humans; Major and Brief Reports; Mutation - genetics; Nucleotide sequence; Phenotyping; Prophylaxis; Quinazolines - pharmacology; Quinazolines - therapeutic use; Randomized Controlled Trials as Topic; Stem cell transplantation; Stem cells; Terminase; Transplants & implants; letermovir; antiviral drug resistance; cytomegalovirus; prophylaxis; RAV

Abstract Background Letermovir (LET), a cytomegalovirus (CMV) deoxyribonucleic acid (DNA) terminase inhibitor, was recently approved for prophylaxis of CMV infection in adult CMV-seropositive recipients of allogeneic hematopoietic stem cell transplantation. Cytomegalovirus genotyping was performed t...